AlarconJane Knight Lowe
    Emeritus Professor of Medicine



    Faculty Office Towers, room 830
    510 20th Street South
    Birmingham, Alabama 35294-3408

    Telephone:(205) 422-0983



    BS,Facultad de Ciencias, Universidad Nacional Mayor de San Marcos. Lima, Perú, 1961
    MD,Facultad de Medicina, Universidad Peruana Cayetano Heredia. Lima, Perú, 1967
    Fellowship (Clinical), Department of Medicine, Johns Hopkins University, School of Medicine. Baltimore City Hospitals, Baltimore, MD, 1969
    Master in Public Health (M.P.H.), Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD, 1972
    Doctor in Medicine, Universidad Peruana Cayetano Heredia. Lima, Perú, 1972
    Fellowship (Research), Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1981


    Selected Honors and Awards

    1964, Diploma presented by the Peruvian Government recognizing voluntary work at the Sierra Indian Communities of Cuzco, Perú

    1971-1972, Recipient of Merck, Sharp & Dohme Scholarship, Master of Public Health, Johns Hopkins University. Baltimore, MD

    1980, American Rheumatism Association Senior Rheumatology Scholar Award

    1988, Mexican Society of Rheumatology, Professor of the Year

    1997, Virginia Engalichteff Award for Impact on Quality of Life, Arthritis Foundation. Denver, CO

    2003, Outstanding Faculty-The University of Alabama at Birmingham Women's Center

    2004, Pfizer Visiting Professor - Vanderbilt University- Nashville, TN

    2006, Keynote Speaker,  Pan American League of Associations of Rheumatologists. Lima, Perú

    2008, ACR Master, ACR Annual Scientifie Meeting, San Francisco, CA

    2008, PANLAR Master, PANLAR Scientific Meeting, Guatemala City, Guatemala

    2009, Dean's Award for Academic Execellence. The University of Alabama at Birmingham, Birmingham, Alabama

    2000-2010, Visiting Professor, Argentinean Society of Rheumatology

    2011, Mexican Society of Rheumatology: Honoring Latin American Masters of the American College of Rheumatology; Cancún, Mexico
             Speaker, Universidad Peruana Cayetano Heredia, 50th year Anniversary. Lima, Perú
             Evelyn Hess Award for Excellence in Lupus Research. Lupus Foundation of America. Chicago, IL

    2012, Leader of Peruvian Rheumatology. Sociedad Peruana de Reumatología; Lima, Perú

    2013, Visiting Professor. University of Washington; Seattle, WA.
              Dr. Honoris Causa. Universidad Nacional de Asunción; Asunción, Paraguay.
              Associate member, Peruvian Academy of Medicine

    2014, Visiting Professor (38th Annual Michael Einbender Distinguished Lectureship. University Missouri; Columbus, MO
              American College of Rheumatology Distinguished Rheumatology Investigator Award, Boston, MA

    2015, Peruvian College of Physicians: Recognition as Leader of Peruvian Rheumatology
             The Servicio de Inmuno-Reumatología, at Hospital Nacional Cayetano Heredia from Universidad Peruana Cayetano Heredia is named: Graciela S. Alarcón

    2016, The University of Alabama at Birmingham establishes the Graciela S. Alarcón, MD, MPH Lupus Research Fund
              The Halsted R. Holman Award for Excellence on Clinical Research in Lupus. LUPUS 2016, Armonk, NY.
              Distinguished Service Award for promoting the goals of the Global Alliance for Musculoskeletal Health.


    Clinical, Research and Education Interests

    I joined the Faculty at UAB in 1981 after being a Research Fellow for about 18 months. I am currently Emeritus Professor and although not in Birmingham, I am still involved in mentoring fellows and collaborating with the LFA, LCTC, GLADEL as the need arises. During my stay at UAB and prior to that at my alma mater (Universidad Peruana Cayetano Heredia in Lima, Perú), I have been involved in the training of clinical and research fellows. In fact, after my US training (1968-1972), I started the first training program in Rheumatology and the first Rheumatology Unit in Perú. Whether in Perú or in the US, I have attended their clinics, have rounded with them, and foremost I have been stimulating them to always keep an open and inquisitive mind in dealing with their day-to-day activities being those in the clinic or in the research setting. I can say that over 60% of the fellows graduating from UAB between 1981 and the early 2000's, when I became more involved in the training of clinical research fellows (vide infra), have had the opportunity to publish their clinical experience under my mentorship and with my unconditional support. Of course, not all of them have become academicians or researchers in their own right, but I have been quick to point out to all of them that the proper appreciation of what research entails or the amount of work that goes into a published paper, can only come from personally going through the same experience.

    Although I have been involved in mentoring Junior Faculty and clinical research fellows in the past, it has been only since 2002 that I have had the opportunity to LUMINAcollaboratorshave the funding to support them for the conduct of research in lupus. These fellows have used the very rich database from LUMINA, a multi-ethnic cohort of lupus patients established in collaboration with Drs. John Reveille (UT-Houston, TX) and Luis Vilá (U- Puerto Rico, San Juan, PR) in the early 1990's. Participating in the training of these young physicians while continuing to mentor Junior Faculty and clinical fellows, as time permits, has been, and continues to be, one of the most rewording but also challenging experiences of my academic life as a rheumatologist. For the most part, these trainees have come with limited research experience; despite that, they have performed spectacularly well. In addition to participating in data collection on patients from the cohort, they have generated their own sub-projects and taken them to completion including the Gladel 2publication of their findings in prestigious rheumatology journals. The fruits of LUMINA have been summarized in a special article published in the Journal Lupus in 2008. Moreover, the salient finding from the LUMINA study were highlighted in an article published in The Rheumatologist in the Spring of 2011. At the present time, I continue to be involved in the work of the fellows that trained with me over the last few years (Drs. Durán-Barragán, González, Pons-Estel and Burgos) who are conducting research in lupus in their country of origin. In parallel I am assisting the LCTC in the establishment of a national registry of lupus patients (US and Canada). Finally, over the last few years I have developed a very close relationship with GLADEL (for Grupo Latinoamericano de Estudio de Lupus or Latin American Group for the Study of Lupus), assisting them in the utilization of their rich database. This group with the support of PANLAR is now developing the Latin American treatment guidelines for lupus, effort in which I am quite involved.



    Click here for a more complete list of publications. Below are selected papers

    Ugarte-Gil MF, Pons-Estel GJ, Molineros J, Wojdyla D, McGwin G Jr, Nath SK, Pons-Estel BA, Alarcón-Riquelme M, Alarcón GS. 2016. Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: A commentary. Rheumatology (Oxford). 55: 436-40. PMID: 26412809; PMC5009444

    Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. 2012. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64: 2677-86. PMID: 22553077; PMC3409311

    Shinjo SK, Bonfá E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, Brenol JC, Chacón-Diaz R, Neira OJ, Berbotto GA, De La Torre IG, Acevedo-Vázquez EM, Massardo L, Barile-Fabris LA, Caeiro F, Silveira LH, Sato EI, Buliubasich S, Alarcón GS, Pons-Estel BA; Grupo Latino Americano de Estudio del Lupus Eritematoso (Gladel). 2010. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 62(3):855-62. PMID: 20131238

    Burgos PI, Perkins EL, Pons-Estel GJ, Kendrick SA, Liu JM, Kendrick WT, Cook WJ, Julian BA, Alarcón GS, Kew II CE. 2009. Risk Factors and Impact of Recurrent Lupus Nephritis in Transplanted Patients with Systemic Lupus Erythematosus: Data from a Single US Institution. Arthritis Rheum 60:2757-66. PMID: 19714623; PMC2771574

    Alarcón GS, McGwin G, Jr., Bertoli AM, Fessler BJ, Calvo-Alén J, Bastian HM, Vilá LM, Reveille JD, for the LUMINA Study Group. 2007. Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. Data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66:1168-72. PMID: 17389655; PMC1955128


  • Ball-2011Professor Emeritus of Medicine


    Faculty Office Tower, room 827

    Telephone: (205) 934-4703




    Dr. Ball joined the UAB faculty in 1965 and was named the Jane Knight Lowe Professor in Medicine in Rheumatology in 1986. UAB recognized and honored his contributions to academic excellence by naming him professor emeritus in 1997.

    In addition to faithfully serving UAB, Dr. Ball has admirably served in leadership roles in numerous professional organizations, committees, and boards. Dr. Ball was the interim director of the division for 18 months in 1995-96. Highly respected by his colleagues as well as his patients, Dr. Ball has cultivated continuing program growth and excellence with a commitment to quality patient care as well as research and education.







  • BennettUABPresidentDr. Bennett received his A.B. from Howard College (Samford University) in 1954, and his M.D. (cum laude) from Harvard Medical School in Boston, Massachusetts in 1958.  He served fellowships at the Massachusetts General Hospital (Rheumatology), the National Institutes of Health (Molecular biology) in Bethesda, Maryland and California Institute of Technology (Molecular Genetics) in Pasadena, California.He returned to Birmingham in 1965 to join the faculty at the University of Alabama at Birmingham (UAB).  From 1970-82, he was Professor and Chair of the Department of Microbiology and Director of the Division of Clinical Immunology and Rheumatology.  In 1982, he was named Professor and Chair of the Department of Medicine, and in 1992 was honored with the William and Evalina Spencer Chair in Medical Science Leadership.  On October 1, 1993, he became the fourth President of the University of Alabama at Birmingham.  In 1997, he was designated by the University Board of Trustees as Distinguished University Professor Emeritus and became President and Chief Operating Officer of BioCryst Pharmaceuticals, Inc. (1997-2008).

    Dr. Bennett has published over 200 scientific papers.  He has been Editor, Cecil Textbook of Medicine, 19th, 20th, and 21st editions (1998-2000); Editor-in-Chief of Arthritis and Rheumatism (1975-1980); Editor-in-Chief of the American Journal of Medicine (1986-97). 

    His contributions in research include the delineation of constant (C) and variable (V) regions of immunoglobulin molecules, based on peptide analyses of myeloma proteins.  These studies resulted in a general hypothesis for the generation of antibody diversity.  These studies also led to description of the phylogenetic development of the immune system and formed the basis for site attachment of complement in activation of the inflammatory pathway.  His clinical research focused on the structures of rheumatoid factors and relationships to various infectious agents as initiators of the rheumatoid process.

    He has received awards from a number of distinguished organizations including the Seale Harris Award, Southern Medical Association (1987); Master, American College of Physicians (1990); Phillips Memorial Award, American College of Physicians (1993); Robert H. Williams Distinguished Chair of Medicine Award, Association of Professors of Medicine (1994); Francis Gilman Blake Award, Association of American Physicians (1997); Master, American College of Rheumatology (1998); Carol Nachman Medal, German Society of Rheumatology (2000); and the Kober Medal from the Association of American Physicians (2000).  He has been awarded honorary degrees by the University of Alabama at Birmingham (D.Sc.1992), the University of Leipzig, Germany (Dr. Med [honoris causa] 1999), and the University of Zurich, Switzerland (Dr. Med [honoris causa] 2008).

    Dr. Bennett has been elected to membership in the American Academy of Microbiology, American Society for Clinical Investigation, the Association of American Physicians, the Institute of Medicine of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Royal Society of Medicine, London, and an honorary member of the Ludwig Heilmeyer Society (Germany).

    His professional activities include President of the American College of Rheumatology (1981-1982); Chair, American Board of Internal Medicine (1994-1995); Chair, Board of Health Sciences Policy, Institute of Medicine, National Academy of Sciences (1988-1993); President, Association of Professors of Medicine (1991-1992); Chairman, Federated Council of Internal Medicine (1992-1993); NIH Director’s Panel on Clinical Research (1995-1998); President of the Association of American Physicians (1996-1997).

    Dr. Bennett has served on many scientific advisory boards, including the Scientific Advisory Committee for Massachusetts General Hospital (1983-1987; 2001-2005); Scientific Advisory Board Merck Sharp & Dohme Research Laboratories (1987-1989); Founding Board Deutsches RheumaForschungsZentrum, Berlin (1988-1998); Scientific Advisory Committee, Warren Alpert Foundation (1989-1997); Scientific Advisory Committee, Charles E. Culpepper Foundation, Inc. (1989-1995); Visiting Committee, Harvard Medical School (1992-1997); and Board of Governors of the Warren Grant Magnuson Clinical Center, at the National Institutes of Health (1996-1999).  


  • Beukelman mug 04 2014 1 crop

    Associate Professor, Division of Pediatric Rheumatology
    Department of Pediatrics

    Secondary Appointment: Division of Clinical Immunology & Rheumatology



    Children's Park Place North, Suite G10
    1601 4th Avenue South
    Birmingham, AL 35233-1711





    BS, University of Illinois, Urbana-Champaign, IL, 1997
    MD, Washington University, Saint Louis, MO, 2001
    Intern (Pediatrics): Cincinnati Children’s Hospital Medical Center, OH, 2002
    Resident (Pediatrics):Cincinnati Children’s Hospital Medical Center, OH, 2004
    Fellow (Pediatric Rheumatology):The Children’s Hospital of Philadelphia, PA, 2007
    M.S.C.E.,University of Pennsylvania, Philadelphia, PA, 2008


    Awards and Honors

    2013 ACR/EULAR International Academic Rheumatology Exchange, Early Career Investigator Delegate

    2013 Member, American Pediatric Society


    Research Description

    Dr. Beukelman’s research is focused on determining the safest and most effective treatments for juvenile idiopathic arthritis (JIA), the most common condition in pediatric rheumatology. He has authored or co-authored more than 60 peer-reviewed publications of original research, as well as several textbook chapters. Dr Beukelman was the lead investigator of the first American College of Rheumatology Recommendations for the Treatment of JIA. Dr Beukelman is the Scientific Director of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, which was established to prospectively evaluate outcomes in the pediatric rheumatic diseases, including the safety and effectiveness of therapeutic agents. He has led several studies using administrative claims data to evaluate the associations between JIA and its treatment and the adverse events of serious infection and cancer.



    Click here for a complete list of publications in PubMed. A few selected papers are below

    Beukelman T, Xie F, Chen L, Baddley JW, Delzell E, Grijalva CG, Patkar NM, Saag KG, Winthrop KL, Curtis JR. 2012. Rates of hospitalized bacterial infection in juvenile idiopathic arthritis and its treatment. Arthritis Rheum  64:2773-80. PMCID: 3409300

    Beukelman T, Haynes K, Curtis JR, Xie F, Chen L, Bemrich-Stolz CJ, Delzell E, Saag KG, Solomon DH, Lewis JD. 2012. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum  64:1263-7. PMCID: PMC3315602

    Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Martini A, Rabinovich CE, Ruperto N. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res  63:465-82. PMCID: PMC3222233



  • Bridges LouAnna Lois WatersEndowed Chair, Division of Clinical Immunology and Rheumatology
    Professor of Medicine
    Director, Division of Clinical Immunology & Rheumatology


    Shelby Building, Room 178C
    1825 University Boulevard

    Administrative Associate: Paula Kiley
    Shelby Building, Room 178B
    1825 University Blvd.
    Birmingham, AL35294-2182
    Fax: 205-934-1564
    Email: pfkiley@uabmc.edu 



    BS, Preprofessional Studies, University of Notre Dame, 1980
    MD,Louisiana State University School of Medicine, 1984
    PhD, University of Alabama at Birmingham, 1995
    Internship and Residency,Internal Medicine, University of Texas Medical Branch, Galveston 1984-1987
    Chief Residency, Internal Medicine, University of Texas Medical Branch, Galveston 1987-1988
    Fellowship, Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 1988-1991


    Research Team

    Stephanie S. Ledbetter, MS Program Manager
    Keith Wanzeck   Lab Manager
    Jinyi Wang Research Associate
    Selena D. Luckett-Smith, RN Study Coordinator
    Laticia Woodruff, RN Study Coordinator
    Dongmei Sun, PhD Database Manager
    Vincent Laufer MD/PhD Student



    Research Description and Potential Projects for Trainees

    My earliest research interest, the role of B lymphocytes and autoantibodies in rheumatoid arthritis (RA), particularly immunoglobulin gene expression and antibody repertoires in synovial tissue, formed the basis of my PhD studies. In addition, my research has focused on identification of genetic influences on RA susceptibility and severity, particularly in African-Americans, and on autoantibodies and biomarkers of treatment response in RA. I have led several multicenter consortia, including the Consortium for the Longitudinal Evaluation of African-Americans with Rheumatoid Arthritis (CLEAR) Registry and Repository; the Biorepository of the Treatment of Early Aggressive RA (TEAR) Trial; and the Treatment Efficacy and Toxicity in RA Database and Repository (TETRAD).



    Click here for a complete list of publications in PubMed.


    Active Research Projects


    Multidisciplinary Clinical Research Center

    As Director of UAB's Multidisciplinary Clinical Research Center (MCRC), funded by NIH P60 AR064172, I oversee a multidisciplinary program to promote research related to the causes, diagnoses, treatments and improved care of patients with arthritis and musculoskeletal diseases. The MCRC contains an Administrative Core, a Methodology Core (led by Xiangqin Cui, PhD, and David Redden, PhD of the UAB Department of Biostatistics, SOPH) and two research projects (see below).

    The mission of the MCRC Methodology Core is to develop and provide state of the art methodology and methodological education in the collaborative support of clinical and translational research in arthritis and musculoskeletal disease (MSD) at the local, regional, national, and international level. Toward this goal, the Core will continue to provide the statistical, epidemiological, outcomes research, statistical genetics, economics/cost effectiveness and bioinformatics leadership and expertise required to develop and perform cutting edge clinical research in arthritis and MSD it pursues four broad goals:

    • To support the design, data collection, management and analytic efforts of the MCRC projects
    • To nurture original research in methodology applicable to clinical research in arthritis and MSD
    • To develop new investigators in the area of arthritis and MSD research
    • To provide methodology seminars, workshops and mini-courses to introduce the newest methodological approaches to the MCRC research base.

    MCRC Project 1. Facilitating Treat-to-Target Strategies Using Novel Health Technology with Decision Support (PI: Jeffrey R. Curtis, MD, MS, MPH). This project will extend and evaluate novel health information technology to enable the systematic collection and integration of Patient Reported Outcome (PRO) and healthcare provider data in routine clinical practice; make use of this data to facilitate patient-provider interaction around optimal use of rheumatoid arthritis (RA) therapies; integrate this data with information in Electronic Health Record (EHR) systems; and demonstrate benefit for both process and outcomes among patients with RA.

    MCRC Project 2. Adaptive Immune Responses to Gut Microbiota in Juvenile and Adult Spondyloarthritis (PI: Charles O. Elson, MD, and Co-PI: Matthew Stoll, MD, PhD, MSCS). This project will integrate cutting-edge technologies of antigen identification with microbiome/metagenome analysis to provide novel information on the microbial contributions to spondyloarthritis. The data will result in new insights into the pathogenesis of SpA, suggest potential new biomarkers for diagnosis and monitoring, and lead to new approaches to therapy by manipulating the microbiota and adaptive immune responses to it.


    Center of Research Translation (CORT) in Gout and Hyperuricemia

    As Co-Director of the UAB CORT in Gout and Hyperuricemia (NIH P50 AR060772 - KG Saag, Contact PI; SL Bridges, Jr., PI), I am involved in three research projects focused on characterizing biomarkers of inflammation (CRP), vascular disease (endothelial function), and blood pressure changes associated with allopurinol (Project 1); examining factors associated with suboptimal gout care and factors influencing effective and safer dosing of allopurinol and colchicine in African-Americans and Caucasians (Project 2); and comparing the effectiveness of a novel pharmacy-based "virtual" Gout Clinic that includes protocol-driven care to usual care in the treatment of chronic gout (Project 3). The overall goal of our CORT (K. Saag, Director) is to improve the health of patients with gout and hyperuricemia by applying scientifically rigorous, state-of-the-art methodology to clinically important questions in translational investigation and to educate clinical investigators through an enrichment program. These innovative projects hold the promise of significant improvements in our understanding of the pathogenesis of gout and related co-morbid conditions, and may ultimately lead to better ways to predict, treat, or prevent gout and hyperuricemia.


    Rheumatic Disease Cores Center

    As Associate Director of the UAB Rheumatic Disease Cores Center (RDCC) (NIH P30 AR048311, John D Mountz, MD, PhD, PI and Director), I serve as collaborate with Dr. Mountz to provide assistance in the strategic planning, management and evaluation functions of the RDCC; and have primary responsibility for the development of Scientific Programs & Career Development program and for the management and monitoring the progress of the Pilot & Feasibility (P&F) Program. The RDCC consists of UAB investigators pursuing research in the rheumatic diseases, the Administrative Core, and three Research Cores: Comprehensive Flow Cytometry Core (CFCC); Analytical Imaging and Immunoreagent Core (AIIC); and Analytical Genomics and Transgenics Core (AGTC).


    VERVE Trial

    I serve as investigator and Director of the Biorepository for the Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (Varicella zostER VaccinE [VERVE]) trial, a randomized, double-blind, placebo-controlled large pragmatic trial to evaluate the immunogenicity, safety, and longer-term effectiveness of the live HZ vaccine in arthritis patients receiving anti-TNF therapy (UM1 AR065705 - JR Curtis, PI).


    TWEAK Trial

    A more recent interest is in mechanisms of muscle inflammation and it impact on mobility after joint replacement for arthritis. Though R01 HD084124 Overcoming TWEAK Signaling to Restore Muscle and Mobility after Joint Replacement (M Bamman, Contact PI/SL Bridges, Jr., MPI), we will test the hypothesis that progressive resistance exercise training plus adjunctive functional mobility training after total hip or knee arthroplasty will more effectively restore muscle mass and mobility function to healthy standards than usual care, particularly in patients with TWEAK (TNF-like weak inducer of apoptosis)-mediated muscle inflammation. We will perform a randomized controlled trial of THA/TKA patients to test this hypothesis and study the cellular and molecular mechanisms of muscle mass regulation.


    National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation

    Our NIH-funded P2C National Resource Center for High-Impact Clinical Trials in Medical Rehabilitation (High-Impact Trials Center, HITC) will serve as a catalyst for the design and implementation of rigorous, high-impact clinical trials to advance medical rehabilitation research. Oversight of the Center is provided by Marcas Bamman, PhD (Director). I serve on the Executive Committee and as Director of the HITC Pilot Component (Pilot-C). The goal of this component is to catalyze the success of medical rehabilitation researchers and interdisciplinary teams by providing consultation, seed funds, key expertise and resources, and ultimately feedback, to medical rehabilitation researchers for the conduct of innovative pilot projects, early-stage proof-of-concept studies, and futility studies needed to shape more definitive clinical trials. The central goal will be met by achieving the following aims: Aim 1. To work closely with the Collaborative Component, providing consultation to medical rehabilitation research teams on how to: 1) Formulate and refine strong and impactful research questions; 2) Identify the goals and aims needed to achieve future clinical outcome trials. Aim 2. To identify and prioritize the most competitive proposals for both pilot studies and voucher funding via an annual peer review process. Aim 3. To provide expertise, resources, and/or mentorship to selected pilot study awardees with ongoing availability during the planning and implementation phases in order to: 1) Bolster the scientific yield of each pilot study; and 2) Position each awardee for a subsequent, highly competitive clinical trial application. Aim 4. To provide constructive and substantive feedback to applicants not selected for funding, and to direct those applicants toward other programs and opportunities within the Center that can strengthen future applications. The Pilot-C will award four $40K pilot studies per year.


    The Rheumatoid Arthritis Synovial Tissue Network

    I served as site PI of the Rheumatoid Arthritis Synovial Tissue Network (REASON) Study (UH2 AR067687 - RM Pope, Northwestern Univ). The goals of this study are to create a new generation of rheumatologists in the United States who will perform minimally invasive ultrasound guided synovial biopsies that is critical for obtaining of synovial tissue from patients at all phases of RA (early, established, DMARD or biologic inadequate response). We have assembled a consortium of leading academic rheumatology groups which includes UAB, Columbia University, Mayo Clinic, Washington University, University of Michigan, and Northwestern University to obtain synovial tissue from RA patients for translational studies to identify novel pathways and potential biomarkers that might predict therapeutic response. We anticipate that we will be part of the NIH Accelerating Medicines Partnership to provide training for synovial biopsy, as well as RA synovial tissue samples to the collaborative research network.


  • ChathamProfessor of Medicine
    Louis W. Heck Clinical Scholar
    Clinical Director, Division of Clinical Immunology & Rheumatology



    Faculty Office Tower (FOT), Room 858
    510 20th Street South

    Telephone:(205) 996-5602



    BSE, Biomedical Engineering, Duke University, 1976
    MD,Vanderbilt University, 1980
    Internship and Residency,Internal Medicine, University of North Carolina Hospital, Chapel Hill, NC, 1980-1983
    Fellowship,Rheumatology, University of Alabama at Birmingham, 1986-1989


    Clinical Interests

    • Lupus
    • Immunodeficiency-associated rheumatic disease
    • Sarcoidosis
    • Auto-inflammatory and macrophage activation syndromes


    Research Description

    Dr. Chatham's research program is focused on the biology of TNF family receptors and their ligands (including BLyS/BAFF) as these relate to disease expression in lupus and other inflammatory/autoimmune disorders. The therapeutic implication of these studies has been extended to current clinical studies that involve the use of monoclonal reagents and soluble receptors targeting BlyS/BAFF in patients with active systemic  lupus as well as their potential use in autoimmunity associated with immunodeficiency. Additional collaborative studies are examining the biology of type-1 interferons and  interferon-alpha blocking reagents on disease activity in systemic lupus and macrophage activation disorders.



    Click here for a more complete list of publications. Below are a few selected papers.

    Chatham W, Chadha A, Fettiplace J, Kleoudis C, Bass D, Roth D, Gordon D.2017. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus. 2017, Jan 1 [Epub ahead of print] PMID: 28467293

    Cron RQ, Chatham WW. 2016. Development of spondyloarthropathy following episodes of macrophage activation syndrome in children with heterozygous mutations in haemophagocytic lymphohistiocytosis-associated genes. Clin Exp Rheumatol. 34(5):953. PMID: 27383696

    Zhang M, Bracaglia C, Prencipe G, Bemrich-Stolz CJ, Beukelman T, Dimmitt RA, Chatham WW, Zhang K, Li H, Walter MR, De Benedetti F, Grom AA, Cron RQ. 2016. A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis.J Immunol. 196(6):2492-503 PMC4779709

    Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group. 2012. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 64(7):2328-37. PMID:22275291 PMCID:PMC3350827

    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group. 2011. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63(12):3918-30. PMID:22127708



  • Curtis2013Harbert Ball Endowed Chair Professor 
    Director, UAB Arthritis Clinical Intervention Program
    Co-Director, UAB Center for Education and Research on Therapeutics (CERTS) of Musculoskeletal Disorders
    Co-Director, UAB PharmacoEpidEmiology and phaRmcoeconomics (PEER) Unit
    University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology



    Faculty Offices Tower, room 802
    510 20th Street South
    Birmingham, AL 35294

    Telephone:(205) 975-2176



    BS (Biology),University of California at San Diego
    MD,Oregon Health & Sciences University, Portland, OR
    MPH,Oregon Health & Sciences University, Portland, OR
    Residency (Internal Medicine):Oregon Health & Science University
    Fellowship (Clinical Immunology and Rheumatology): University of Alabama at Birmingham
    MS (Epidemiology), Harvard School of Public Health
    Postdoctoral (Clinical Informatics):Stanford University


    Research and Clinical Interests

    Dr. Jeffrey Curtis is a Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). Dr. Curtis received a Medical Degree (MD) and a Master of Public Health (MPH) degree from Oregon Health & Sciences University in Portland, OR. He subsequently completed a residency in internal medicine at Oregon Health & Science University and a fellowship in rheumatology at UAB. He completed a graduate program in Clinical Informatics at Stanford University and received his Master of Science (MS) degree in epidemiology at the Harvard School of Public Health. He is board certified in both rheumatology and clinical informatics.

    Dr. Curtis currently holds the William J. Koopman Endowed Professorship in Rheumatology and Immunology at UAB. He is the Co-Director of the UAB Center for Education and Research on Therapeutics (CERTs) of Musculoskeletal Disorders, which has a major emphasis on evaluating the safety and comparative effectiveness of medications for rheumatic diseases. Additionally, as the Director of the UAB Arthritis Clinical Intervention Program, he leads the clinical trials unit for the rheumatology division at UAB, with a particular focus on rheumatoid arthritis (RA) and psoriatic arthritis (PsA). He is the Co-Director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research (PEER) Unit. PEER uses multiple large data sources to study comparative effectiveness questions across multiple chronic diseases. These data sources include national administrative data from Medicare and commercial health plans, electronic health record data, and large registries. In 2012, he was awarded the Henry Kunkel Young Investigator Award by the American College of Rheumatology (ACR) and was accepted into the American Society for Clinical Investigation (ASCI) in 2016.

    The evaluation of the efficacy, comparative effectiveness, and safety of the medications used to treat rheumatoid arthritis and spondyloarthritis are among Dr. Curtis’s research interests. He served on the Core Expert Panel for the ACR’s 2008, 2012, and 2015 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA. He was the Deputy Director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality (AHRQ), and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources. He is the Co-PI of the PCORI-funded Patient Powered Research Network “Arthritis-Power” registry, focused on RA, psoriasis, and psoriatic arthritis. He also leads the multi-center NIH-funded large pragmatic randomized controlled trial “VERVE” studying the safety and effectiveness of the live herpes zoster vaccine in patients receiving biologic agents. He is a member of the Center for Disease Control (CDC) Advisory Committee on Immunization Practices (ACIP) Herpes Zoster workgroup. In 2015, he was appointed as a member to the FDA Arthritis Advisory Committee.

    Dr. Curtis also studies risk factors for and outcomes of osteoporosis. He was a member of the ACR’s task force to update recommendations for the management of glucocorticoid induced osteoporosis (GIOP). He served on the ASBMR Task Force on Atypical Subtrochanteric and Diaphyseal Fractures.

    Dr. Curtis is a member of the American College of Rheumatology (ACR), the International Society for Pharmacoepidemiology (ISPE), the American Medical Informatics Association (AMIA), and the American Society of Bone and Mineral Research (ASBMR). He has been on the editorial board for Arthritis & Rheumatism, Pharmacoepidemiology and Drug Safety (PDS) and Arthritis Care and Research (AC&R). He has authored more than 350 peer-reviewed manuscripts, review articles and book chapters.



    Click here for a complete list of publications. Below are a few selected papers.

    Curtis JR, McVie T, Mikuls T, Reynolds, RJ, Navarro I, O’Dell J, Moreland L, Bridges SL, Ranganath, VK, Cofield SS. 2013. Clinical Response with 12 Weeks as a Predictor of Future Low Disease Activity in Early Rheumatoid Arthritis Patients: Results from the TEAR Trial. Journal of Rheumatology. PMID 23588939; PMC 3694569

    Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E. 2012. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 64(10):1480-9. PMID: 22833479 PMC3687540

    Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. 2012. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 308(1):43-9. PMID: 22760290

    Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, Cavet G, Centola M, Hesterberg LK, Chernoff D, Ford K, Shadick NA, Hamburger M, Fleischmann R, Keystone E, Weinblatt ME. 2012. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 64(12):1794-803. PMID: 22736476

    Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Liu L, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. 2011. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 306(21):2331-9. PMC3428224



  • Sam Dalvi 16Assistant Professor of Medicine

    Division of Clinical Immunology and Rheumatology


    Faculty Offices Tower (FOT)
    510 20th Street South
    Birmingham, AL35294

    Telephone: (205) 996-5602



    B.S./B.A.: Auburn University, 2001
    M.D.: University of Alabama at Birmingham, 2005
    Internship:University of Alabama at Birmingham, 2006
    Residency:University of Alabama at Birmingham, 2008
    Fellowship: New York University Hospital for Joint Diseases, 2012


    Research Interests

    Dr. Dalvi’s research interests involve the role of environmental stimuli in the development of autoimmunity as well as the role of lead toxicity and gouty arthritis. In addition, he is planning to develop a vasculitis registry to investigate potential markers of disease activity in patients with vasculitis.


    Clinical Interests

    Dr. Dalvi’s main clinical interests include the following: Giant cell/temporal arteritis, Takayasu’s arteritis, polymyalgia rheumatic (PMR), Granulomatosis with polyangiitis (Wegener’s disease), Microscopic polyangiitis, Eosinophilic granulomatosis with polyangiitis (Churg-Strauss disease), Polyarteritis nodosa (PAN), cutaneous vasculitis, cryoglobulinemic syndromes, drug-induced vasculitis..

    He also has a strong clinical interest in the following conditions:

    Rheumatoid arthritis
    Pseudogout (CPPD)
    Systemic Lupus Erythematosus
    Psoriatic arthritis
    Ankylosing spondylitis

    Antiphospholipid antibody syndrome
    Behcet’s syndrome
    Sjogren’s syndrome
    Relapsing Polychondritis



    Dalvi, SR, Moser, DW; Samuels, J. 2013. Ultrasound and Treatment Algorithms of RA and JIA. Rheumatic Disease Clinics of North America. 39(3):669-88). PMID: 23719081

    Dalvi, SR, Pillinger, MH. 2013. Saturnine gout, redux: a review. American Journal of Medicine. 126:450.e1-450.e8. PMID: 23510947

    Dalvi, SR, Yildirim, R; Santoriello, D; Belmont, HM. 2012. Pseudo-pseudo Meigs' syndrome in a patient with systemic lupus erythematosus. Lupus. 21:1463-1466. PMID: 22983642

    Dalvi, SR, Yildirim, R; Yazici, Y. 2012. Behcet's Syndrome. Drugs. 72:2223-2241. PMID: 23153327



  • Danila 2017Associate Professor of Medicine
    Ambulatory Clinical Director, Rheumatology


    Faculty Office Tower, room 838
    510 20th Street South, Birmingham, AL 35294-3408

    Patient care telephone: (205) 996-7438
    Patient care fax: (205) 583-8060
    Email: mdanila@uab.edu

    Administrative Assistant:
    Patricia Taylor
    Telephone: (205) 996-5602
    Fax: (205) 934-4198


    MD,“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
    Internship (General Medicine),“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
    MSc (Microbiology),University of Victoria, Victoria, BC, Canada
    Residency in Internal Medicine,University of Illinois at Chicago-Advocate Christ Medical Center, Oak Lawn, IL
    Clinical Rheumatology Fellow, University of Alabama at Birmingham
    MSPH (Epidemiology), School of Public Health, University of Alabama at Birmingham
    Graduate Certificate in Health Quality and Safety, School of Health Professions, University of Alabama at Birmingham

    Clinical Interests

    • Rheumatoid Arthritis
    • Connective tissue associated interstitial lung disease
    • Sjogren's syndrome
    • Scleroderma


    Research Interests

    Dr. Danila is an Associate Professor of Medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham (UAB). Dr. Danila is an implementation scientist and outcome researcher, passionate about improving the quality, effectiveness and processes/delivery of medical care for patients. Her research program focuses on two main areas: i) the design and evaluation of culturally-adapted and literacy-appropriate health care interventions that improve outcomes for patients with chronic conditions; and ii) the development and implementation of strategies to assist physicians and other health care professionals in engaging in shared decision making and evidence-based clinical practice.

    Dr. Danila is also interested in the redesign of healthcare delivery processes, decreasing healthcare costs and increasing value-based medical care. She has been actively involved as volunteer for the American College of Rheumatology (ACR). She served on the ACR Insurance Subcommittee (ISC) from 2012-2016.



    Click here for a list of publications.


  • Gaffo Oct2015Associate Professor of Medicine
    Associate Director, Rheumatology Fellowship Training Program
    Rheumatology Section Chief, Birmingham VA Medical Center



    Shelby Bldg., room 306

    Telephone:(205) 975-8909



    MD:Universidad Peruana Cayetano Heredia, 1991-1999, Lima, Peru 
    Residency: Internal Medicine, University of Alabama at Birmingham, 2002-2005

    Rheumatology, University of Alabama at Birmingham, 2005-2007
    Quality Improvement, National VA Quality Scholars Program at the Birmingham VA Medical Center, 2007-2009

    Postgraduate:MSPH in Epidemiology, University of Alabama at Birmingham School of Public Health, 2006-2008)


    Clinical Interests

    • General Rheumatology Practice with emphasis in connective tissue diseases and metabolic crystal disorders.
    • Quality improvement in musculoskeletal disease.
    • Care of patients with vasculitis


    Research interests

    • Epidemiology of hyperuricemia and gout, with focus on their association with ethnic, dietary, and cardiovascular factors
    • Quality of care in arthritis and rheumatic diseases
    • Clinical and therapeutic aspects of vasculitis care



    Click here for a more complete list of publications. Below are selected papers

    Sattui SE, Singh JA, Gaffo AL. 2014. Comorbidities in patients with crystal diseases and hyperuricemia. Rheum Dis Clin North Am. 40(2):251-78. PMID: 24703346 PMCID: PMC4159668

    Gaffo AL, Jacobs DR Jr, Sijtsma F, Lewis CE, Mikuls TR, Saag KG. 2012. Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort. Ann Rheum Dis. 2012 Sep 14. [Epub ahead of print]PMID:22984170

    Gaffo AL, Jacobs DR Jr, Lewis CE, Mikuls TR, Saag KG. 2012. Association between being African-American, serum urate levels and the risk of developing hyperuricemia: findings from the Coronary Artery Risk Development in Young Adults cohort. Arthritis Res Ther. 14(1):R4. PMID:22225548

    Gaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R, Chen L, Dalbeth N, Sivera F, Vázquez-Mellado J, Chou CT, Zeng X, Perez-Ruiz F, Kowalski SC, Goldenstein-Schainberg C, Chen L, Bardin T, Singh JA. 2012. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum. 64(5):1508-17. PMID:22083456



  • Beatriz Hanaoka 2016 BAssistant Professor of Medicine

    Division of Clinical Immunology and Rheumatology


    Shelby Building, Room 210
    1825 University Boulevard

    Telephone: (205) 930-8347

    Fax: (205) 930-8340

    Email: bhanaoka@uabmc.edu



    M.D. University of Sao Paulo, Brazil, 2005
    Residency: (Internal Medicine), Cleveland Clinic Foundation, Cleveland, OH, 2005-2008
    Fellowship: (Rheumatology) Columbia University, NY, 2008-2010


    Research Interests

    Dr. Hanaoka is conducting clinical studies to understand the reasons behind the decline in skeletal muscle function and physical activity in patients with rheumatic diseases, particularly in rheumatoid arthritis (RA). Her research is primarily focused on understanding at a mechanistic level the metabolic and physiologic abnormalities of skeletal muscle in RA patients. More specifically, she is investigating if insulin resistance is an underlying cause of skeletal muscle dysfunction in RA patients by conducting clinical trials utilizing an insulin sensitizer. This research is being supported by a K23 NIAMS patient-oriented career development award.

    Dr. Hanaoka is also conducting additional collaborative studies with her husband, Dr. Prabha Nagareddy (UAB - Nutrition Sciences), and Dr. Andrew Murphy (Baker IDI Institute, Melbourne, Australia) to examine the molecular pathways that contribute to increased cardiovascular disease risk in RA patients.



    Click here for a more complete list of publications. Below are selected papers

    Cleary LC, Crofford LJ, Long D, Charnigo R, Clasey J, Beaman F, Jenkins KA, Fraser N, Srinivas A, Dhaon N, Hanaoka BY. 2015. CT based muscle density predicts muscle function and health-related quality of life in patients with idiopathic inflammatory myopathies. Arthritis Care Res. 67(7):1031-40. PMID: 25623494

    Hanaoka BY, Cleary LC, Long DE, Srinivas A, Jenkins KA, Bush HM, Starnes CP, Rutledge M, Duan J, Fan Q, Fraser N, Crofford LJ. 2015. Physical impairment in patients with idiopathic inflammatory myopathies is associated with the American College of Rheumatology functional status measure. Clinical Rheumatology. 34(11);1929-37. PMID: 25388646

    Hanaoka BY, Peterson CA, Crofford LJ. 2012. Glucocorticoid effects on skeletal muscle: benefit and risk in patients with autoimmune inflammatory rheumatoid diseases. Expert Review in Clinical Immunology. 8(8):695-7. PMID: 23167679

    Hanaoka BY, Peterson CA, Horbinski C, Crofford LJ. 2012. Implications of glucocorticoid therapy in idiopathic inflammatory myopathies. Nat. Rev. Rheumatol. 8: 448-457. PMID: 22688888


  • Heck-2011Professor of Medicine


    Faculty Office Tower, Room 858B




    MD, Indiana University School of Medicine, 1973
    Internship, Indiana University Hospitals
    Residency, Indiana University Hospitals
    Postdoctoral Training, Harvard Medical School

    Research Interests

    Pathogenesis and treatment of rheumatoid arthritis.

    Selected Publications

    Chaiamnuay S, Heck LW, Bell WC, Bastian HM. 2007. Acute granulomatous lupus pneumonitis: the first case report. Lupus. 16(3):201-4. Review. PMID: 17432106

    Brandt KD, Mazzuca SA, Katz BP, Lane KA, Buckwalter KA, Yocum DE, Wolfe F, Schnitzer TJ, Moreland LW, Manzi S, Bradley JD, Sharma L, Oddis CV, Hugenberg ST, Heck LW. 2005. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. Arthritis Rheum. 52(7):2015-25. PMID: 15986343

    Moreland LW, Morgan EE, Adamson TC 3rd, Fronek Z, Calabrese LH, Cash JM, Markenson JA, Matsumoto AK, Bathon J, Matteson EL, Uramoto KM, Weyand CM, Koopman WJ, Heck LW, Strand V, Diveley JP, Carlo DJ, Nardo CJ, Richieri SP, Brostoff SW. 1998. T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides. Arthritis Rheum. 41(11):1919-29. PMID: 9811045

    Moreland LW, Heck LW Jr, Koopman WJ. 1997. Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum. 40(3):397-409. Review.  PMID: 9082924

    Jaworski TM, Bradley LA, Heck LW, Roca A, Alarcón GS. 2005. Development of an observation method for assessing pain behaviors in children with juvenile rheumatoid arthritis. Arthritis Rheum. 38(8):1142-51. PMID: 7639812



  • laura_hughesProfessor of Medicine
    Director, Rheumatology Fellowship Training Program



    Shelby Bldg, Room 178G
    1825 University Blvd.

    Telephone: (205) 934-7995
    Fax:(205) 996-6734



    BS (Zoology), Auburn University, Auburn, Alabama, 1991, cum laude
    MD, University of Alabama at Birmingham, Birmingham, Alabama, 1996, with Scholastic Excellence
    Internship and Residency (Internal Medicine), Carraway Methodist Medical Center, Birmingham, Alabama, 1996-1999
    Chief Resident (Internal Medicine), Carraway Methodist Medical Center, Birmingham, Alabama, 1999-2000
    Clinical Fellow (Internal Medicine), Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama , 2001-2003
    MSPH (Clinical Trials/Biostatistics), University of Alabama at Birmingham, Birmingham, Alabama, 2001-2003


    Research Interests:

    Dr. Hughes’ research interest is in identifying pharmacogenetic markers for treatment response and toxicity in subjects with rheumatoid arthritis. She has also investigated genetic markers for susceptibility and severity in African-American subjects with rheumatoid arthritis. Her research interests have recently expanded to include analysis of genetic markers in inflammatory and adipokine genes for association with osteoarthritis.



    Click here for a more complete list of publications. Below are a few selected papers.

    Tamhane A, McGwin G Jr, Redden DT, Hughes LB, Brown EE, Westfall AO, Reynolds RJ, Conn DL, Jonas BL, Smith EA, Brasington RD, Moreland LW, Bridges SL Jr, Callahan LF. 2013. Complementary and alternative medicine use in african-americans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 66(2):180-189. PMID:23983105

    Reynolds RJ, Cui X, Vaughan LK, Redden DT, Causey Z, Perkins E, Shah T, Hughes LB; CLEAR Investigators, Damle A, Kern M, Gregersen PK, Johnson MR, Bridges SL Jr. 2013. Gene expression patterns in peripheral blood cells associated with radiographic severity in African Americans with early rheumatoid arthritis. Rheumatol Int. 33(1):129-37. PMID:22238028 PMCID:PMC3769702

    Perkins EA, Landis D, Causey ZL, Edberg Y, Reynolds RJ, Hughes LB, Gregersen PK, Kimberly RP, Edberg JC, Bridges SL Jr; Consortium for the Longitudinal Evaluation of African Americans with Early Rheumatoid Arthritis Investigators. 2012. Association of single-nucleotide polymorphisms in CCR6, TAGAP, and TNFAIP3 with rheumatoid arthritis in African Americans. Arthritis Rheum. 64(5):1355-8. PMID:22127930

    Guermazi A, Roemer FW, Hayashi D, Crema MD, Niu J, Zhang Y, Marra MD, Katur A, Lynch JA, El-Khoury GY, Baker K, Hughes LB, Nevitt MC, Felson DT. 2011. Extended report: assessment of synovitis with contrast-enhanced MRI using a whole-joint semiquantitative scoring system in people with, or at high risk of, knee osteoarthritis: the MOST study. Ann Rheum Dis. 70(5):805-11.  PMID: 21187293

    Hughes LB, Reynolds RJ, Brown EE, Kelley JM, Thomson B, Conn DL, Jonas BL, Westfall AO, Padilla MA, Callahan LF, Smith EA, Brasington RD, Edberg JC, Kimberly RP, Moreland LW, Plenge RM, Bridges SL Jr. 2010. Most common single-nucleotide polymorphisms associated with rheumatoid arthritis in persons of European ancestry confer risk of rheumatoid arthritis in African Americans. Arthritis Rheum. 62(12):3547-53. PMID: 21120996



  • RevTracy Hwangpo smallInstructor of Medicine

    Division of Clinical Immunology and Rheumatology


    Shelby Building, Room 412
    1825 University Boulevard
    Birmingham, AL 35294-1711

    Telephone: (205) 934-7427

    Fax: (205) 934-1564

    Email: thwangpo@uabmc.edu


    (Biology with Honors): Haverford College, 2000
    Ph.D.(Biomedical Sciences): Mount Sinai's Graduate School of Biomedical Sciences, 2007
    M.D.: Icahn School of Medicine at Mount Sinai, 2008
    Intern (Medicine): University of Alabama at Birmingham School of Medicine, Birmingham, AL, 2008-2009
    Resident (Medicine): University of Alabama at Birmingham School of Medicine, Birmingham, AL, 2009-2011
    Postdoctoral Fellow (Immunology): University of Alabama at Birmingham School of Medicine, Birmingham, AL, 2011-2014
    Clinical Fellow (Allergy & Immunology), University of Alabama at Birmingham School of Medicine, Birmingham, AL, 2012-2014

    Research Interests


    The focus of my research is the characterization of immune abnormalities in patients with recurrent sino-pulmonary infections with subnormal immunoglobulin levels, who do not meet criteria for Common Variable Immunodeficiency (CVID). As a clinician, I am interested in classifying those patients, as well as patients with classical CVID by severity and following the course of changes in their immune system to find clues that may suggest ways to treat their unspecified immunodeficiency. As a researcher, I have used several criteria to explore the immune abnormalities in this specific cohort: (a) Changes in B cell subsets as a function of time; (b) Functional antibody response; (c) HLA typing to examine the propensity for development of immunodeficiency; and (d) Examination of rare SNPs that may correlate with the severity of their immune system abnormalities.



    Wang Y, Hwangpo T, Martin MP, Vince N, Qi Y, Reynolds RJ 4th, Absher D, Gao X, Ballinger CA, Burrows PD, Atkinson TP, Brown EE, Elgavish A, Liu C, Carrington M, Schroeder HW.J 2016. Killer cell immunoglobulin-like receptors are associated with common variable immune deficiency pathogenesis. Allergy Clin Immunol. 138:1495-1498. PMID: 27665490 PMCID: PMC5104182

    Mroczek, E, Ippolito, GC, Rogosch, T, Hoi, KH, Hwangpo, TA, Brand, MG Zhuang, Y, Liu,C, Schneider, D, Zemlin, M, Brown, EE, Georgiou, G, and Schroeder, HW. Differences in the composition of the human antibody repertoire by B cell subsets in the blood. Front. Immunol. 5:96, 2014. PMCID: PMC3958703

    Hwangpo, TA, Jordan, JD, Premsiriut,P, Jayamaran, G, Licht, J, Iyengar, R, and Neves, SR. GRIN modulates Sprouty repression of MAPK activation by growth factor stimulation. Journal of Biological Chemistry 287(17):13674-85. 2012. PMCID: PMC3340172




  • JainAssistant Professor of Medicine
    Division of Clinical Immunology & Rheumatology


    Faculty Office Tower, room 834
    510 20th Street South

    Telephone:(205) 934-1532



    MD,Maulana Azad Medical College, Delhi University, New Delhi, India, 2001
    Internship(Internal Medicine), St. Francis Hospital, Evanston, IL, 2003-2004
    Residency (Internal Medicine), St. Francis Hospital, Evanston, IL, 2004-2005
    Chief Resident (Internal Medicine), St. Francis Hospital, Evanston, IL, 2005-2006


    Research and Clinical Interests

    Clinical interests include inflammatory arthritis, SLE, vasculitides, inflammatory myopathies, utilization of musculoskeletal ultrasound as a tool for evaluation of rheumatic disease. Main research interest is the safety of biological therapies in rheumatic diseases.


    Selected Publications

    Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 64(5):625-39. PMCID: PMC4081542

    Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain, A, Volkman, ER, Agrawal, H, Bae, S, Mudano, AS, Patkar, NM, Saag, KG.2012 Update of the 2008 American College of Rheumatology (ACR) Recommendations for the use of Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and Biologics in the treatment of Rheumatoid Arthritis (RA). Arthritis Care Res64(5):625-39. PMID: 22473917

    Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, Finckh A et al. 2010. A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. Semin Arthritis Rheum.40(1):2-14.e1.PMID: 20674669

    Curtis JR, Patkar NM, Jain A, Greenberg J, Solomon DH. 2009. The Validity of Physician-Reported Hospitalized Infections in an Observational U.S. Arthritis Registry. Rheumatology (Oxford).48(10):1269-72. PMID: 19654217



  • kimberly CCTS croppedHoward L. HolleyProfessor of Medicine

    Director, UAB Center for Clinical and Translational Science


    Shelby Building, Room 172D
    1825 University Boulevard

    Telephone:(205) 934-0245


    Program Manager I: Ms. Ronda Smith
    Shelby Building, Room 172D
    1825 University Blvd.
    Birmingham, AL35294-2182
    Fax: 205-934-1564
    Email: rhsmith@uab.edu 


    Princeton University
    BA, University of Oxford, Oxford, England
    MA (Physiology), University of Oxford, Oxford, England
    MD,Harvard Medical School
    Internship,University of Pennsylvania
    Residency, University of Pennsylvania Hospital
    Fellowship, Arthritis and Rheumatism Branch, NIAMS/NIH
    Fellowship, Hospital for Special Surgery, Cornell Medical Center
    Fellowship, Rheumatic Diseases, Hospital for Special Surgery, Cornell Medical Center

    Research Description

    Dr. Kimberly is an internationally recognized translational scientist with substantial experience in the development and administration of large, multi-site and multiple-investigator scientific programs.  His research group is interested in the role of genetic factors in the normal function of the immune system and in the development of autoimmune and immune-mediated inflammatory diseases such as systemic lupus erythematosus (SLE) and systemic vasculitis. The group’s approach has focused on receptors for immunoglobulin (Fc receptors) as a model system and has explored molecular mechanisms of receptor signaling and the molecular basis for receptor polymorphisms in humans. Allelic variations in receptor structure profoundly affect receptor function. The team has been a leader in developing several national and international research consortia for the study of human diseases, and they have demonstrated that certain low-binding alleles are enriched in SLE patients. More active alleles are over-represented in patients with vasculitis and severe renal disease. As prominent contributors in major population-based genome wide association studies, the group is pursuing other genes and gene families as they are identified as candidate genes. These genes include complement receptors, cytokine genes and their promoters, signal transduction molecules, and members of the TNF superfamily. In addition to identifying susceptibility alleles, these studies have led to molecular insights into responsiveness to Ig-based therapeutics.



    Click here for a more complete list of publications. Below are a few selected papers.

    Kelley JM, Monach PA, Ji C, Zhou Y, Wu J, Tanaka S, Mahr AD, Johnson S, McAlear C, Cuthbertson D, Carette S, Davis JC Jr, Dellaripa PF, Hoffman GS, Khalidi N, Langford CA, Seo P, St Clair EW, Specks U, Stone JH, Spiera RF, Ytterberg SR, Merkel PA, Edberg JC, Kimberly RP. 2011. IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. Proc Natl Acad Sci U S A. 108(51):20736-41. PMID:22147912

    Li X1, Wu J, Ptacek T, Redden DT, Brown EE, Alarcón GS, Ramsey-Goldman R, Petri MA, Reveille JD, Kaslow RA, Kimberly RP, Edberg JC. 2013. Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses. Sci Transl Med. 5(216):216ra175. PMCID:PMC3982386

    Freedman BI1, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarcón GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KL, Niewold TB, Patel NM, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP; Lupus Nephritis–End‐Stage Renal Disease Consortium. 2014. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 66(2):390-6. PMCID:PMC4002759




  • WKoopmanDistinguished Professor
    Chairman Emeritus of Medicine


    Faculty Office Tower, room 802

    Telephone: (205) 996-5047
    Fax: (205) 934-4198

    Research and Clinical Interests and Achievements

    In nearly 30 years at UAB, Dr. Koopman has earned worldwide recognition for defining the critical role synovial tissue cells play in rheumatoid arthritis. His insights into the molecular biology of the disease have inspired groundbreaking treatment options, including arthritis-fighting proteins, a monoclonal antibody, and even a vaccine. He also led UAB’s rheumatology programs to national prominence as director of the clinical immunology and rheumatology division and as founding director of the Arthritis and Musculoskeletal Diseases Center. Since 1995 Koopman has held the Spencer Chair in Medical Science Leadership, overseeing the launch of new divisions and research centers. He also sowed the seeds of scientific discovery as chair of the UAB Research Advisory Group, a collaboration of researchers focused on streamlining the funding process. 

    The Koopman File:

    • Only UAB faculty member to have held three endowed chairs
    • Helped establish UAB’s largest privately sponsored research program with Japan’s Sankyo pharmaceutical company
    • Listed among the most cited scientists by Clinical Medicine
    • Member of the National Academy of Science’s Institute of Medicine and Britain’s Royal Society of Medicine; winner of the Carol-Nachman Prize in rheumatology research
    • Chaired scientific counselor board for National Institute of Arthritis and Musculoskeletal and Skin Diseases
    • Former president of the American Society for Clinical Investigation and American College of Rheumatology
    • 2011 Recipient of the Presidential Gold Medal from the American College of Rheumatology
    • 2012 Laureate of the American College of Physicians, Alabama Chapter


    Selected Publications

    Koopman WJ.
    2008. Dawn of the era of biologics in the treatment of the rheumatic diseases. Arthritis Rheum. 58(2 Suppl):S75-8. No abstract available. PMID: 18240221

    Yang X, Wang J, Liu C, Grizzle WE, Yu S, Zhang S, Barnes S, Koopman WJ, Mountz JD, Kimberly RP, Zhang HG. 2005. Cleavage of p53-vimentin complex enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of rheumatoid arthritis synovial fibroblasts. Am J Pathol. 167(3):705-19. PMID: 16127151

    Ichikawa K, Liu W, Fleck M, Zhang H, Zhao L, Ohtsuka T, Wang Z, Liu D, Mountz JD, Ohtsuki M, Koopman WJ, Kimberly R, Zhou T. 2003. TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol. 171(2):1061-9. PMID: 12847280

    Xu Y, Szalai AJ, Zhou T, Zinn KR, Chaudhuri TR, Li X, Koopman WJ, Kimberly RP. 2003. Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J Immunol. 171(2):562-8. PMID: 12847219

    Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, Zhou T. 2001. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med. 7(8):954-60. PMID: 11479629

    Koopman WJ. 2001. Prospects for autoimmune disease: Research advances in rheumatoid arthritis. JAMA. 285(5):648-50. PMID: 11176875

    Rundle CH, Schroeder HW Jr, Koopman WJ. 1998. In situ hybridization analysis of immunoglobulin heavy chain variable gene expression with family specific oligonucleotide probes. J Immunol Methods. 218(1-2):31-52. PMID: 9819121

    Moreland LW, Morgan EE, Adamson TC 3rd, Fronek Z, Calabrese LH, Cash JM, Markenson JA, Matsumoto AK, Bathon J, Matteson EL, Uramoto KM, Weyand CM, Koopman WJ, Heck LW, Strand V, Diveley JP, Carlo DJ, Nardo CJ, Richieri SP, Brostoff SW. 1998. T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides. Arthritis Rheum. 41(11):1919-29. PMID: 9811045

    Baggott JE, Morgan SL, Koopman WJ. 1998. The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion. Arthritis Rheum. 41(8):1407-10. PMID: 9704638

    Lee SK, Song CH, Kim JB, Chwae YJ, Choi IH, Bridges SL Jr, Koopman WJ, Schroeder HW Jr. 1998. Enhanced expression of immunoglobulin kappa light chains with unusually long CDR3 regions in patients with rheumatoid arthritis. J Rheumatol. 1925(6):1067-71. PMID: 9632065

    Clausen BE, Bridges SL Jr, Lavelle JC, Fowler PG, Gay S, Koopman WJ, Schroeder HW Jr. 1998. Clonally-related immunoglobulin VH domains and nonrandom use of DH gene segments in rheumatoid arthritis synovium. Mol Med. 4(4):240-57. PMID: 9606177



  • Sarah-MorganProfessor of Medicine
    Medical Director, Osteoporosis Clinic, Center for Metabolic Bone Disease


    830 Faculty Office Tower
    510 20th Street South
    Birmingham, AL 35294-3408

    Telephone:(205) 934-3235
    Fax:(205) 934-4602



    BS (Nutrition and Dietetics), Iowa State University, 1977
    BS (Nutrition and Related Sciences), Iowa State University, 1977
    MD, The University of Iowa, 1981
    Internship and Residence (Internal Medicine), University of Iowa Hospitals and Clinics, Iowa City, 1981-1984
    Fellowship (Clinical Nutrition), The University of Alabama at Birmingham, 1984-1986
    MS (Nutrition), The University of Alabama at Birmingham, 1987



    C.E. Butterworth Award, UAB - 1986
    Outstanding Young Alumna, Iowa State University, 1991
    Outstanding Young Alumna, UAB Department of Nutrition Sciences, School of Health Related Professions
    Distinguished Achievement Citation, Iowa State University, 1999
    Outstanding UAB Woman Faculty Member, 2001
    Distinguished Alumlnus Award for Achievement, University of Iowa 2007
    UAB School of Health Professions - Member of "Fab 40" - 2009
    Sam Brown Bridge Builder Award, UAB, 2010
    President, International Society for Clinical Densitometry, 2011-2012


    Research Description

    Dr. Morgan's research program has been focused on methotrexate and folic acid metabolism in patients with rheumatoid arthritis.  Her work with Dr. Joseph E Baggott and members of the Division of Clinical Immunology and Rheumatology (Drs. Graciela Alarcon, Dr. William Koopman, Dr. S Louis Bridges, and Dr. Laura Hughes) have established the folic acid supplementation during low dose methotrexate therapy for rheumatoid arthritis lowers toxicity without affecting efficacy.  Drs Morgan and Baggott have also studied purine metabolism and methotrexate therapy in rat adjuvant arthritis and participate in trials related to methotrexate pharmacogenetics.  Dr. Morgan and Dr. Baggott have also investigated the effects of a medical food on osteoarthritis.

    As the Medical Director of the UAB Osteoporosis Prevention and Treatment Clinic, Dr. Morgan has an interest in bone densitometry and clinical trials related to osteoporosis.



    Click here for a more complete list of publications. Below are selected papers.

    Morgan SL, Prater GL. 2017 Quality in dual-energy X-ray absorptiometry scans. Bone. 2017 Jan 31. [Epub ahead of print] PMID: 28159711

    Lewiecki EM, Binkley N, Morgan SL, Shuhart CR, Camargos BM, Carey JJ, Gordon CM, Jankowski LG, Lee JK, Leslie WD. 2016. Best practices for dual-energy x-ray absorptiometry measurement and reporting: International Society for Clinical Densitometry Guidance. J Clin Densitom 10: 127-40. PMID: 27020004

    Baggott JE, Bridges SL, Morgan SL.  2005. Evidence for two phenotypes in the metabolism of methotrexate to 7-hydroxymethotrexate in patients with rheumatoid arthritis.  Arthritis Rheum 52: 356-358. PMID: 15641087

    Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarcón GS. 1994. Supplementation with folic acid during methotrexate therapy of rheumatoid arthritis: results from a double-blind, placebo-controlled trial.  Ann Intern Med 121: 833-841. PMID:7978695

    Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcón GS.  1990. The effect of folic acid supplementation on the toxicity of low-dose methotrexate treatment of rheumatoid arthritis.  Arthritis Rheum 33:  9-18. PMID: 2405864




SOM Epilogue Menu